Mental Health

Cipralex superiority supported by new data

Published in Drug Week, March 31st, 2006

Lundbeck presented new clinical data for Cipralex (escitalopram) in major depression at the International Anxiety Disorders Conference in Stellenbosch, South Africa, showing superiority of Cipralex in comparison with Paxil/Seroxat (paroxetine).

Cipralex is an allosteric serotonin-reuptake inhibitor antidepressant, which has consistently shown significant efficacy, fast onset of action, and excellent tolerability in the treatment of depression and anxiety disorders in multiple clinical trials, according to the company. Superior efficacy of Cipralex in comparison with other existing antidepressants has been established in other clinical trials and several meta-analyses,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2006-03-31)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry